AUA Guidelines: Vasectomy

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Richard Lee, MD, MBA

To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/vasectomy-guideline

AUA Guidelines: Vasectomy Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Richard Lee, MD, MBA To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/vasectomy-guideline

AUA Guidelines: Vasectomy

Update Series (2026): Evaluating Abnormal Urine Cytology Without Clinically Demonstrable Urinary Tract Disease

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Sherri M. Donat, MD

Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

Update Series (2026): Evaluating Abnormal Urine Cytology Without Clinically Demonstrable Urinary Tract Disease Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Sherri M. Donat, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

Update Series (2026): Evaluating Abnormal Urine Cytology Without Clinically Demonstrable Urinary Tract Disease

AUA2024: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management 

CME Available: https://auau.auanet.org/node/41040

At the conclusion of this activity, participants will be able to:
1. Identify clinically available data that can help assess risk of UTUC disease.
2. Verbalize the important role of kidney function before and after nephroureterectomy in the management of UTUC, and calculate the estimated new baseline glomerular filtration rate.
3. Compare the clinical trial data on intravesical, neoadjuvant and adjuvant chemotherapy.
4. Recognize the possibility of an undiagnosed inheritable syndrome in patients with UTUC, ask about history of nongenitourinary cancers, and identify the clinical methods for screening and diagnosis of inheritable syndromes.
5. Recognize the importance of preoperative chemotherapy and response-based surgical management for locoregional nodal recurrence after nephroureterectomy.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Merck & Co., Inc., UroGen Pharma, Inc.

AUA2024: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management CME Available: https://auau.auanet.org/node/41040 At the conclusion of this activity, participants will be able to: 1. Identify clinically available data that can help assess risk of UTUC disease. 2. Verbalize the important role of kidney function before and after nephroureterectomy in the management of UTUC, and calculate the estimated new baseline glomerular filtration rate. 3. Compare the clinical trial data on intravesical, neoadjuvant and adjuvant chemotherapy. 4. Recognize the possibility of an undiagnosed inheritable syndrome in patients with UTUC, ask about history of nongenitourinary cancers, and identify the clinical methods for screening and diagnosis of inheritable syndromes. 5. Recognize the importance of preoperative chemotherapy and response-based surgical management for locoregional nodal recurrence after nephroureterectomy. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Merck & Co., Inc., UroGen Pharma, Inc.

AUA2024: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management 

CME Available: https://auau.auanet.org/node/41040

At the conclusion of this activity, participants will be able to:
1. Identify clinically available data that can help assess risk of UTUC disease.
2. Verbalize the important role of kidney function before and after nephroureterectomy in the management of UTUC, and calculate the estimated new baseline glomerular filtration rate.
3. Compare the clinical trial data on intravesical, neoadjuvant and adjuvant chemotherapy.
4. Recognize the possibility of an undiagnosed inheritable syndrome in patients with UTUC, ask about history of nongenitourinary cancers, and identify the clinical methods for screening and diagnosis of inheritable syndromes.
5. Recognize the importance of preoperative chemotherapy and response-based surgical management for locoregional nodal recurrence after nephroureterectomy.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Merck &amp; Co., Inc., UroGen Pharma, Inc.

AUA2024: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management

AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

CME Available: https://auau.auanet.org/node/41015

At the conclusion of this activity, participants will be able to:
1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)
2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists.
3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB
4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents
5. Discuss potential future pharmacological pathways and therapies for OAB.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Astellas

AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider CME Available: https://auau.auanet.org/node/41015 At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB) 2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists. 3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents 5. Discuss potential future pharmacological pathways and therapies for OAB. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas

AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

AUA2021 State-Of-The-Art Lecture: Robotic Ureteroscopy

Moderator: Prokar Dasgupta, MD 			
3D Printing : Jamie Landman, MD			
Assessment of Surgical Competence: Andrew Hung, MD

Moderator: Prokar Dasgupta, MD 3D Printing : Jamie Landman, MD Assessment of Surgical Competence: Andrew Hung, MD

AUA2021 Panel Discussion: Artificial Intelligence Applications In Urology

AUA2021 State-Of-The-Art Lecture: Pain Management In FPMRS Surgery

Moderator: Nelson Bennett, MD            
Panel:
Hypogonadism: Mohit Khera, MD
Erectile Dysfunction: Alan Shindel, MD
Telemedicine: Faysal Yafi, MD
Infertility: Ranjith Ramasamy, MD

Moderator: Nelson Bennett, MD Panel: Hypogonadism: Mohit Khera, MD Erectile Dysfunction: Alan Shindel, MD Telemedicine: Faysal Yafi, MD Infertility: Ranjith Ramasamy, MD

AUA2021 Panel Discussion: COVID And Sexual Medicine

AUA2021 John Duckett Memorial Lecture: Nephron Sparing Surgery In The Management Of Wilms Tumor

AUA2021 Journal Of Urology Lecture - The Promises And Pitfalls Of Large Database Studies

AUA2021 Ramon Guiteras Lecture - Three Decades Of Bladder Cancer Treatment: Progress And Promise

Title: AUA2021 John K. Lattimer Lecture - Kidney Stones: Is Prevention Possible? 
Speaker: Glenn M. Preminger, MD
Release: January 12

Title: AUA2021 John K. Lattimer Lecture - Kidney Stones: Is Prevention Possible? Speaker: Glenn M. Preminger, MD Release: January 12

AUA2021 John K. Lattimer Lecture - Kidney Stones: Is Prevention Possible?

Host: Jay Raman, MD, FACS
Co-host: Scott Eggener, MD

Host: Jay Raman, MD, FACS Co-host: Scott Eggener, MD

Testis Cancer – Apply the Guidelines to Clinical Practice

How to Safely and Properly Administer Immunotherapies Podcast (2021)

CME Available: https://auau.auanet.org/node/33496

ACKNOWLEDGEMENTS
This educational series is supported by independent educational grants from:
Astellas
AstraZeneca
Lantheus Medical Imaging
Merck
Pfizer, Inc.

How to Safely and Properly Administer Immunotherapies Podcast (2021) CME Available: https://auau.auanet.org/node/33496 ACKNOWLEDGEMENTS This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.

How to Safely and Properly Administer Immunotherapies

The AUAUniversity podcast is an official podcast of the American Urological Association.  More information can be found at https://auau.auanet.org

Education

The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org

Share AUAUniversity

Sign up to save your podcasts

AUAUniversity

AUAUniversity episodes

About AUAUniversity

More shows like AUAUniversity

Freakonomics Radio

Planet Money

ChooseFI | Financial Independence Podcast

White Coat Investor Podcast

The Indicator from Planet Money

The Peter Attia Drive

AUANews Inside Tract

Fiction - Comedy Fiction

GU Cast | Urology Podcast

Huberman Lab

Urology COViD

BackTable Urology

EAU Podcast

Urology Audio Guidelines

Urology Times Podcasts